OrthoPediatrics commenced U.S. launch of QuickPack™ synthetic bone graft substitute through a private label partnership with Graftys.
With mechanical properties close to those of cancellous bone, QuickPack produces a calcium-deficient apatite that has similar composition and structure to natural bone mineral. The product is supplied in a closed loop double-syringe delivery system, eliminating the need for open air mixing, and temporarily fills defects to allow new bone formation during the healing process.
Joe Hauser, OrthoPediatrics’ Vice President of Trauma & Deformity Correction, commented, “With the domestic launch of QuickPack, we further our mission to surround our surgeon customers with all modalities to treat their patients. The addition of this innovative bone void filler cement to our product offering is another demonstration of our ability to acquire and enhance proven technologies. We look forward to expanding our hospital and customer base through this new partnership.”
OrthoPediatrics commenced U.S. launch of QuickPack™ synthetic bone graft substitute through a private label partnership with Graftys.
With mechanical properties close to those of cancellous bone, QuickPack produces a calcium-deficient apatite that has similar composition and structure to natural bone mineral. The product is supplied in a...
OrthoPediatrics commenced U.S. launch of QuickPack™ synthetic bone graft substitute through a private label partnership with Graftys.
With mechanical properties close to those of cancellous bone, QuickPack produces a calcium-deficient apatite that has similar composition and structure to natural bone mineral. The product is supplied in a closed loop double-syringe delivery system, eliminating the need for open air mixing, and temporarily fills defects to allow new bone formation during the healing process.
Joe Hauser, OrthoPediatrics’ Vice President of Trauma & Deformity Correction, commented, “With the domestic launch of QuickPack, we further our mission to surround our surgeon customers with all modalities to treat their patients. The addition of this innovative bone void filler cement to our product offering is another demonstration of our ability to acquire and enhance proven technologies. We look forward to expanding our hospital and customer base through this new partnership.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
